Head-To-Head Contrast: Neoleukin Therapeutics (NASDAQ:NLTX) Versus Abliva AB (Publ) (OTCMKTS:NEVPF)
Head-To-Head Contrast: Neoleukin Therapeutics (NASDAQ:NLTX) Versus Abliva AB (Publ) (OTCMKTS:NEVPF)
Neoleukin Therapeutics (NASDAQ:NLTX – Get Rating) and Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.
新白金治療 (NASDAQ: NLTX — 獲得評分) 和阿卜麗華 AB (公司) (OTCMKTS: NEVPF — 獲取評級) 都是小型股醫療公司, 但哪個是更好的投資?我們將根據兩家企業的風險，收益，分析師建議，股息，盈利能力，機構所有權和估值來對比這兩家企業。
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and recommmendations for Neoleukin Therapeutics and Abliva AB (publ), as reported by MarketBeat.com.
據 MarketBeat.com 報導，這是新白金治療和艾卜力娃 AB（publ）的最新評分和建議的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neoleukin Therapeutics | 1 | 6 | 0 | 0 | 1.86 |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 新白細胞治療 | 1 | 6 | 0 | 0 | 1.86 |
| 艾卜麗瓦 AB (公主) | 0 | 0 | 0 | 0 | N/A |
Neoleukin Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 825.21%. Given Neoleukin Therapeutics' higher possible upside, equities analysts plainly believe Neoleukin Therapeutics is more favorable than Abliva AB (publ).
新白金治療目前的共識目標價為 6.00 美元，表明潛在的上行空間為 825.21％。鑑於新白金治療的可能較高的上行空間，股票分析師清楚地認為新白金治療比 Aliva AB（publ）更有利。
Profitability
盈利
This table compares Neoleukin Therapeutics and Abliva AB (publ)'s net margins, return on equity and return on assets.
此表比較了新白金治療和 Aliva AB（publ）的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Neoleukin Therapeutics | N/A | -47.87% | -41.17% |
| Abliva AB (publ) | N/A | N/A | N/A |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 新白細胞治療 | N/A | -47.87% | -41.17% |
| 艾卜麗瓦 AB (公主) | N/A | N/A | N/A |
Insider & Institutional Ownership
內幕和機構所有權
44.0% of Neoleukin Therapeutics shares are owned by institutional investors. 13.8% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
44.0％ 的新白金治療股份由機構投資者擁有。13.8％ 的新白金治療股份由公司內部人士擁有。強大的機構所有權表明對沖基金，捐贈基金和大型資金經理認為股票有望實現長期增長。
Valuation & Earnings
估值及收益
This table compares Neoleukin Therapeutics and Abliva AB (publ)'s revenue, earnings per share (EPS) and valuation.
此表格比較新白金治療和 Aliva AB (publ) 的收入、每股收益 (EPS) 和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neoleukin Therapeutics | N/A | N/A | -$60.69 million | ($1.08) | -0.60 |
| Abliva AB (publ) | $20,000.00 | 201.51 | -$14.40 million | ($0.04) | -0.25 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 新白細胞治療 | N/A | N/A | -60.69 萬美元 | (一元八元) | -0.60 |
| 艾卜麗瓦 AB (公主) | 二萬美元 | 201.51 | -一千四百四十萬元 | (0.04 美元) | -0.25 |
Abliva AB (publ) has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
ABLIVA AB（publ）的收入和收入比新白金治療更高。與 Aliva AB（publ）相比，Neoleukin 治療以較低的價格盈利比進行交易，這表明它目前兩隻股票中價格更便宜。
Summary
摘要
Abliva AB (publ) beats Neoleukin Therapeutics on 6 of the 9 factors compared between the two stocks.
ABLIVA AB（PUBL）在 6 的 9 因素之間比較兩個股票之間擊敗新白金治療。
About Neoleukin Therapeutics
關於新白金治療
(Get Rating)
(取得評分)
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Neoleukin 治療有限公司是一家生物製藥公司，該公司的計算方法來設計新蛋白質治療。該公司滿足腫瘤學、炎症和自體免疫方面的重要醫療需求。其主要候選產品 NL-201 是一種組合的 IL-2 和 IL-15 受體激動劑，旨在消除 α 受體結合。該公司由丹尼爾·阿德里亞諾·席爾瓦，卡爾·沃爾基和烏穆特烏爾赫於 2003 年 12 月成立，總部位於華盛頓州西雅圖。
About Abliva AB (publ)
關於阿卜麗娃 AB（公司）
(Get Rating)
(取得評分)
Abliva AB operates as a biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. Its projects include KL1333 and NV354. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.
Aliva AB 是一家生物製藥公司，致力於治療原發性線粒體疾病的藥物的研究和開發。其項目包括 KL1333 和 NV354。該公司由埃斯基爾·埃爾默於 2000 年 2 月 1 日成立，總部位於瑞典隆德。
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收新白金治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Neoleukin 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。